Literature DB >> 1805487

Cyclosporin in steroid-resistant auto-immune haemolytic anaemia.

S Dündar1, O Ozdemir, O Ozcebe.   

Abstract

A case of Evans' syndrome which was refractory to conventional and high dose steroid treatment and to splenectomy was treated with cyclosporin, beginning with the dose of 10 mg/kg/day and then gradually tapering to 4 mg/kg/day. The patient experienced excellent benefit from cyclosporin; his haematological parameters were completely normal at the 12th month of therapy, without any side effect of the drug.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1805487     DOI: 10.1159/000204834

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  4 in total

Review 1.  Glucocorticoid-resistant asthma.

Authors:  Tuck-Kay Loke; Ana R Sousa; Christopher J Corrigan; Tak H Lee
Journal:  Curr Allergy Asthma Rep       Date:  2002-03       Impact factor: 4.806

2.  Second-line therapy in paediatric warm autoimmune haemolytic anaemia. Guidelines from the Associazione Italiana Onco-Ematologia Pediatrica (AIEOP).

Authors:  Saverio Ladogana; Matteo Maruzzi; Piera Samperi; Annalisa Condorelli; Maddalena Casale; Paola Giordano; Lucia D Notarangelo; Piero Farruggia; Fiorina Giona; Agostino Nocerino; Silvia Fasoli; Maria L Casciana; Maurizio Miano; Fabio Tucci; Tommaso Casini; Paola Saracco; Wilma Barcellini; Alberto Zanella; Silverio Perrotta; Giovanna Russo
Journal:  Blood Transfus       Date:  2018-04-13       Impact factor: 3.443

Review 3.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

4.  Successful treatment with cyclosporine and high-dose gamma immunoglobulin for persistent parvovirus B19 infection in a patient with refractory autoimmune hemolytic anemia.

Authors:  Shigeki Ito; Tatsuo Oyake; Toshiyuki Uchiyama; Takeshi Sugawara; Kazunori Murai; Yoji Ishida
Journal:  Int J Hematol       Date:  2004-10       Impact factor: 2.490

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.